What changed from existing technology?
This study shows that a process called ISGylation helps cancer cells in the colon to grow by making them more efficient at using energy.
This study is the first to show that ISGylation directly affects the stability and activity of ALDOA and PKM2 in colorectal cancer metabolism, which was not previously understood.
Commercialization signals visible at publication
This is not a success probability or investment opinion. It prioritizes follow-up using evidence available when the paper was published.
Verified evidence · 0
- 시제품·장치 구현 근거 미확인
- 제조·규모 확장 근거 미확인
- 장기·실사용 검증 근거 미확인
Later patent, company, clinical, and production events are added separately only after verification.
Patent check: Not checked yetCurrent technology stage: Validation stage
See what changed before reading the full paper.
What still needs to be solved?
Repeated real-world validation, manufacturability, cost, and long-term stability still require follow-up evidence.
What could change if this succeeds?
This finding could lead to new therapeutic strategies targeting ISGylation to treat colorectal cancer by disrupting its metabolic effects.
Keep following this technology
Revisit changes when new papers, patents, company participation, validation, or products appear.